Graduate studies at Western
Philosophy, Ethics, and Humanities in Medicine 3 (1):1-15 (2008)
|Abstract||The left ventricular assist device was originally designed to be surgically implanted as a bridge to transplantation for patients with chronic end-stage heart failure. On the basis of the REMATCH trial, the US Food and Drug Administration and the US Centers for Medicare & Medicaid Services approved permanent implantation of the left ventricular assist device as a destination therapy in Medicare beneficiaries who are not candidates for heart transplantation. The use of the left ventricular assist device as a destination therapy raises certain ethical challenges. Left ventricular assist devices can prolong the survival of average recipients compared with optimal medical management of chronic end-stage heart failure. However, the overall quality of life can be adversely affected in some recipients because of serious infections, neurologic complications, and device malfunction. Left ventricular assist devices alter end-of-life trajectories. The caregivers of recipients may experience significant burden (e.g., poor physical health, depression, anxiety, and posttraumatic stress disorder) from destination therapy with left ventricular assist devices. There are also social and financial ramifications for recipients and their families. We advocate early utilization of a palliative care approach and outline prerequisite conditions so that consenting for the use of a left ventricular assist device as a destination therapy is a well informed process. These conditions include: (1) direct participation of a multidisciplinary care team, including palliative care specialists, (2) a concise plan of care for anticipated device-related complications, (3) careful surveillance and counseling for caregiver burden, (4) advance-care planning for anticipated end-of-life trajectories and timing of device deactivation, and (5) a plan to address the long-term financial burden on patients, families, and caregivers. Short-term mechanical circulatory devices (e.g. percutaneous cardiopulmonary bypass, percutaneous ventricular assist devices, etc.) can be initiated in emergency situations as a bridge to permanent implantation of ventricular assist devices in chronic end-stage heart failure. In the absence of first-person (patient) consent, presumed consent or surrogate consent should be used cautiously for the initiation of short-term mechanical circulatory devices in emergency situations as a bridge to permanent implantation of left ventricular assist devices. Future clinical studies of destination therapy with left ventricular assist devices should include measures of recipients' quality of end-of-life care and caregivers' burden|
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
|Through your library||Configure|
Similar books and articles
Katrina A. Bramstedt (1999). Left Ventricular Assist Devices: An Ethical Analysis. Science and Engineering Ethics 5 (1):89-96.
Felicitas Kraemer (2013). Ontology or Phenomenology? How the Lvad Challenges the Euthanasia Debate. Bioethics 27 (3):140-150.
Mohamed Y. Rady & Joseph L. Verheijde (2010). Retraction: End-of-Life Discontinuation of Destination Therapy with Cardiac and Ventilatory Support Medical Devices: Physician-Assisted Death or Allowing the Patient to Die? BMC Medical Ethics 11 (1):20-.
Elin Palm (2013). Who Cares? Moral Obligations in Formal and Informal Care Provision in the Light of ICT-Based Home Care. Health Care Analysis 21 (2):171-188.
Daniel Friedrich (2013). A Duty to Adopt? Journal of Applied Philosophy 30 (1):25-39.
Esther Loon & Teun Zuiderent-Jerak (2012). Framing Reflexivity in Quality Improvement Devices in the Care for Older People. Health Care Analysis 20 (2):119-138.
Sue Ross, Magali Robert, Marie-Andrée Harvey, Scott Farrell, Jane Schulz, David Wilkie, Danny Lovatsis, Annette Epp, Bill Easton, Barry McMillan, Joyce Schachter, Chander Gupta & Charles Weijer, Ethical Issues Associated With the Introduction of New Surgical Devices, or Just Because We Can, Doesn't Mean We Should.
Alain L. Bardou, Pierre M. Auger, Jean-Luc Chasse & Renaud Seigneuric (1997). Theoretical Study of Cardiac Transient Conduction Blocks on Reentries Induction. Applications to Antiarrhythmic Drugs. Acta Biotheoretica 45 (3-4).
R. G. Seigneuric, J.-L. Chassé, P. Auger & A. Bardou (2005). Simulated Interactions Between a Class III Antiarrhythmic Drug and a Figure 8 Reentry. Acta Biotheoretica 53 (4).
Annemaire Mol (2000). What Diagnostic Devices Do: The Case of Blood Sugar Measurement. Theoretical Medicine and Bioethics 21 (1):9-22.
Alain L. Bardou, Pierre M. Auger, Soumeya Achour, Philippe Dumee, Pierre J. Birkui & Marie-Claude Govaere (1995). Effect of Myocardial Infarction and Ischemia on Induction of Cardiac Reentries and Ventricular Fibrillation. Acta Biotheoretica 43 (4).
Fiona Randall (1996). Palliative Care Ethics: A Good Companion. Oxford University Press.
Sue Ross, Charles Weijer, Amiram Gafni, Ariel Ducey, Carmen Thompson & Rene Lafreniere (2010). Ethics, Economics and the Regulation and Adoption of New Medical Devices: Case Studies in Pelvic Floor Surgery. BMC Medical Ethics 11 (1):14-.
Jan Nespor (2011). Devices and Educational Change. Educational Philosophy and Theory 43 (5-6):15-37.
Added to index2010-08-24
Total downloads13 ( #95,599 of 739,349 )
Recent downloads (6 months)1 ( #61,538 of 739,349 )
How can I increase my downloads?